By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#121 – Azra Raza, M.D.: Why we’re losing the war on cancer
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Oncologist Azra Raza Argues Cancer Research Fails Patients; Early Detection Offers Hope
- Raza says she wrote The First Cell after decades as an oncologist, lab researcher and cancer widow, and after the failure of oncologists to help Andrew, a 22-year-old friend of her daughter with glioblastoma.
- She argues that the core treatments are still slash, poison and burn, that age-adjusted cancer mortality is about what it was in 1930, and that the recent decline tracks reduced smoking.
- Raza and Attia discuss how marginal survival gains from expensive drugs, such as a $45,000 version of seven-and-three for AML, bring financial ruin to patients and are enabled by lowered FDA bars and misaligned incentives.
- Raza says 95 percent of experimental cancer agents fail because preclinical models like cell lines and mice are artificial, and that much of the published literature is irreproducible.
- Her proposed solution is to shift far more resources, around 50 percent instead of 5, to prevention and early detection using human tissue, biomarkers and blood-based tests, and she ends optimistically, pointing to her 60,000-sample tissue repository.
IDEAS WORTH REMEMBERING
5 ideasOverall cancer mortality progress is largely explained by smoking declines
Raza says age-adjusted mortality today is the same as in 1930, and the recent drop follows an earlier rise from smoking, so it mostly parallels the decline in smoking.
Celebrated successes cover only a small share of cancers
Raza lists CML with Gleevec, acute promyelocytic leukemia, lymphomas, myeloma and melanoma as the big wins, but says together they account for under 10 percent of cancers, while 68 percent of new cases are cured mainly by surgery, radiation and chemo.
Small survival gains carry enormous costs
Raza describes a liposomal seven-and-three costing $45,000 versus $5,000, with a 3.7-month median survival improvement in highly selected patients, and cites that 42 percent of patients are financially ruined by the second year.
Preclinical models are a major reason for drug failure
Raza says cell lines undergo transcriptomic drift away from their tissue of origin and that animal findings do not extrapolate to humans, contributing to the 95 percent failure rate; she would not rely on animals even for safety.
Incentives across the system discourage a paradigm change
Raza and Attia discuss how academia's publishing and trial-opening pressures, pharma's shareholder duty, and nonprofit hospitals' profits all push away from patient-centered outcomes, with Raza invoking the boiling frog.
WORDS WORTH SAVING
5 quotesIn twenty twenty, you know what it is? It is the same as it was in nineteen thirty.
— Azra Raza
For me, it's like I'm running around looking for an adult in the room.
— Azra Raza
It's like trying to use a map to find your way in London, but you're using a map of Paris. It's not going to work.
— Azra Raza
Stop studying animals, for God's sake. Study human tissue.
— Azra Raza
instead of spending five percent in prevention, let's spend fifty percent in prevention and early detection. That is all I'm asking for.
— Azra Raza
High quality AI-generated summary created from speaker-labeled transcript.
